Yes, which is another very good reason SAS Cat B prescriptions will be limited exactly as per the Anavex PR as opposed to all the persistent silly revenue speculation.
And if there are no SAEs to report then it is not an issue. Since the folks that are taking 2-73 have been taking it for 5 years it seems that the chances of an SAE are pretty low at this point.
Your argument about not expanding the SAS Cat B population makes a lot of sense. There doesn't seem to be much upside for the company and a significant possible downside.